Alexion Pharmaceuticals was Downgraded to a Hold Rating at J.P. Morgan

By Ryan Adsit

J.P. Morgan analyst Anupam Rama downgraded Alexion Pharmaceuticals (NASDAQ: ALXN) to Hold today. The company’s shares opened today at $111.41, close to its 52-week low of $102.47.

According to TipRanks.com, Rama is a 1-star analyst with an average return of -2.7% and a 48.1% success rate. Rama covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Clearside Biomedical, and PTC Therapeutics.

Currently, the analyst consensus on Alexion Pharmaceuticals is Moderate Buy and the average price target is $166, representing a 49.0% upside.

In a report released today, Oppenheimer also reiterated a Hold rating on the stock.

Alexion Pharmaceuticals’ market cap is currently $25.85B and has a P/E ratio of 55.22. The company has a book value ratio of 2.9194.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.